FDA Letter Puts Novo Nordisk GLP-1 Risks And Valuation In Focus
Find your next quality investment with Simply Wall St’s easy and powerful screener, trusted by over 7 million…
Novo Nordisk Faces FDA Scrutiny As Hims Partnership Reshapes GLP‑1 Outlook
Get insights on thousands of stocks from the global community of over 7 million individual investors at Simply…
Feds warn Ozempic and Wegovy maker over failure to report side-effects from weight-loss drugs
Millions of Americans use injectable drugs like Novo Nordisk’s Ozempic and Wegovy to help them lose weight –…
FDA Warning Letter Puts Novo Nordisk Compliance And Valuation In Focus
Find winning stocks in any market cycle. Join 7 million investors using Simply Wall St’s investing ideas for…
FDA Warns Novo Nordisk of Unreported GLP-1 Side Effects
The FDA has issued a warning letter to Novo Nordisk saying the maker of Ozempic and Wegovy failed…
FDA warns Novo Nordisk of potential unreported GLP-1 side effects
The Food and Drug Administration issued a warning letter to Novo Nordisk — the maker of Ozempic and…
Novo Nordisk Addresses FDA Concerns with Action Plan
Novo Nordisk, the Danish pharmaceutical giant, announced on Tuesday it had received a warning letter from the…